Background {#Sec1}
==========

Colorectal cancer is one of the most common gastrointestinal malignant tumours in the world and has one of the highest rates of morbidity and mortality worldwide. It is not only the third most common malignancy in United States but also the third leading cause of cancer-related deaths \[[@CR1]\]. Rectal cancer accounts for between 27% and 58% of all cases of colorectal cancer, with variations attributable to the cancer registry studied and the method used to classify rectosigmoid tumours \[[@CR2]\]. Of the 304,930 new cases of digestive-tract cancer diagnosed in 2016 in the United States, 39,220 were rectal, with higher incidence seen among males than females (23,110 vs. 16,110) \[[@CR1]\]. Further information about the global incidence of rectal cancer can be obtained from the World Health Organization (WHO)-GLOBOCAN \[[@CR3], [@CR4]\].

A distinction must be made between rectal and colon carcinoma, as rectal cancer has a distinct dissemination pattern. Furthermore, surgical resection is the mainstay of curative treatment for rectal adenocarcinomas \[[@CR5]\]. Colon carcinoma is located in the peritoneal cavity, an area that is highly accessible and facilitates surgical intervention with wide resection margins. In contrast, rectal cancer is located extraperitoneally, within the pelvis, thus it makes harder the surgical resection that in most of cases involve low anterior or abdominoperineal resection. Some rectal tumours are superficial (T0/T1) and small enough (\< 3 cm) to be successfully resected by local excision. However, most patients have more deeply invasive tumours that are adherent or fixed to adjoining structures (e.g., sacrum, pelvic sidewalls, prostate, or bladder) that requires more extensive resection \[[@CR6]\].

Rectal tumours tend toward local recurrence, and surgery alone only provides a high cure rate for patients with early-stage disease \[[@CR7]\]. In fact, the five-year survival rate for patients with stage I tumours is around 80 to 90%, while this rate is below 80 for those with stage II or III disease \[[@CR8]\].

To increase long-term survival, the Swedish Study Group has introduced neoadjuvant treatment for locally advanced tumours based on chemotherapy combined with radiation \[[@CR9]\]. The effects of chemoradiotherapy are the results of DNA damage produced directly by ionizing radiations; or indirectly, by the action of chemical radicals generated from ionization \[[@CR10]\]. Chemoradiotherapy improves survival rates and local recurrence by reducing tumour size and stage, and also has the ability to achieve pathologic downstaging \[[@CR11], [@CR12]\]. For these reasons, neoadjuvant chemotherapy is the standard of care for stage II--III rectal tumours, not only to increase the effectiveness of radiotherapy but also to attain negative surgical margins \[[@CR13]\] and enhance the possibility for sphincter-preserving surgery \[[@CR14]\]. As described by Ryan et al., tumour regression grade is a useful method of scoring pathologic response to chemoradiotherapy in rectal carcinomas \[[@CR15]\]. However, complete pathological response has been reported in only 10% to 30% of patients, and around 40% show partial or no response \[[@CR16]\].

To predict response to neoadjuvant treatment, translational research has focused on the search for potential biomarkers of response to preoperative treatment \[[@CR17]--[@CR19]\].

DEK was identified fusioned with the CAN nucleoporin due to the translocation t (6;9) in a subtype of acute myeloid leukemia \[[@CR20]\]. DEK is overexpressed in multiple neoplasms, including bladder cancer \[[@CR21]\], breast cancer \[[@CR22]\], glioblastoma \[[@CR23]\], hepatocellular carcinoma \[[@CR24]\], melanoma \[[@CR25]\], retinoblastoma \[[@CR26], [@CR27]\], and other types, such as oral, ovarian, or uterine-cervical cancer \[[@CR28]--[@CR31]\].

Functionally, DEK is involved in the DNA damage repair machinery from the interaction with PARP-1 \[[@CR32]\], suppresses apoptosis, senescence, differentiation, and promotes cell transformation both in vitro and in vivo \[[@CR33]--[@CR35]\]. Our group has previously associated DEK expression with adjuvant-treatment response in colorectal cancer \[[@CR36]\]. Here, we observed a significant increase in apoptotic cells after the combination of irinotecan treatment and DEK knock-down, compared to those treated with irinotecan or DEK knock-down individually. However, this effect was not observed with 5FU or oxaliplatin treatments alone or in combination with DEK knock-down \[[@CR36]\].

DEK has also been described to have a high statistical power to predict pathological complete response for neoadjuvant chemotherapy in breast cancer \[[@CR37]\].

Therefore, our hypothesis to link DEK with neoadjuvant therapy in rectal cancer has been based on the above-mentioned reports that associated DEK with treatment response.

This study aimed to explore the precise role of DEK as a novel biomarker of pathologic response in rectal adenocarcinoma. To achieve this, 74 biopsies obtained from pre-treated locally advanced rectal-adenocarcinoma patients were immunostained with DEK. Association with neoadjuvant chemoradiotherapy response was assessed in light of these findings.

Methods {#Sec2}
=======

Patient samples {#Sec3}
---------------

The follow-up of 91 consecutive patients with stage II or stage III rectal adenocarcinoma according to American Joint Committee on Cancer \[[@CR38]\] who underwent standardized neoadjuvant chemoradiotherapy followed by total mesorectal excision, from December 2006 to January 2014, were reviewed for the study. However, only those patients with available endoscopic biopsies for immunohistochemical analysis were selected for this study. A total of 74 patients with locally advanced rectal adenocarcinoma, from General and Digestive-Tract Surgery Department of University Hospital Fundación Jiménez Díaz were assessed for eligibility.

Sixty-three percent of the rectal tumours included in the study were determined to be of a high grade based on the recommendations of the College of American Pathologists \[[@CR39]\]. Magnetic resonance imaging (MRI), computed tomography, endorectal ultrasound, and/or endoscopy revealed a high prevalence of stage III tumours (93%). The criteria published by Ryan et al. were applied to classify patients according to response to neoadjuvant treatment \[[@CR15]\]. According to this classification system, complete pathological response was indicated by an absence of tumour cells; partial pathologic response by fibrosis with presence of isolated tumour cells; and minimum pathologic response by tumour nests outgrown by fibrosis or no tumour kill. T- and N-downstaging were also assessed. Radiotherapy administered as neoadjuvant treatment was dosed over 28 sessions (45 Gy to the pelvic area and 50.4 Gy to the tumour area).

Tissue microarray {#Sec4}
-----------------

Samples from 74 patients were used to construct a paraffin block containing 148 cores (2 cores per patient) to allow for immunohistochemistry analysis. A hollow needle (MTA-1 tissue arrayer, Beecher Instruments, Sun Prairie, USA) was used to perform a punch biopsy from pre-selected tumour areas in paraffin-embedded (FFPE) tissues. These tissue cores were then inserted in a recipient paraffin block. Sections from this FFPE block were cut using a microtome and mounted on a microscope slide to be analyzed by immunohistochemistry.

Immunohistochemistry and quantification {#Sec5}
---------------------------------------

Staining was conducted in 2-μm sections. Slides were deparaffinized by incubation at 60 °C for 10 min and then incubated with PT-Link (Dako, Denmark) for 20 min at 95 °C in a high pH-buffered solution. To block endogenous peroxidase, holders were incubated with peroxidase blocking reagent (Dako, Denmark). Biopsies were stained for 20 min with a 1:50 dilution of DEK antibody (610,948, BD Biosciences) and with 1:150 of phospho-P38 (ab38238, Abcam) followed by incubation with anti-Ig horseradish peroxidase-conjugated polymer (EnVision, Dako, Denmark) to detect antigen-antibody reaction. A single human normal rectum tissue was used as a positive control for immunohistochemical staining. Sections were then visualized with 3,3′-diaminobenzidine as the chromogen for 5 min and counterstained with hematoxylin. Photographs were taken with a stereo microscope (Leica DMi1, Wetzlar, Germany). Immunoreactivity was quantified by two independent pathologists as the percentage of positive stained cells over the total number of tumour cells. Positiveness was defined as medium to high DEK expression levels according to *The Human Protein Atlas* (<http://www.proteinatlas.org>) and quantification of each biopsy was calculated using the average of both cores.

Statistical analysis {#Sec6}
--------------------

The association between DEK expression (categorized as low or high percentage of positive stained cells) and clinicopathologic variables, including pathologic response, was evaluated by *Fisher's exact* or Chi-square (χ^2^) test. χ^2^ test was used to analyze the relationship between DEK expression and clinicopathologic parameters. *Fisher's exact* test was used when one or more variable had a frequency of five or less. Association between phospho-P38 expression (categorized as low or high percentage of positive stained cells) with pathologic response was assessed by *Fisher's exact* test. Association between DEK and phospho-P38 expression was analysed by χ^2^ test. *P* values ≤0.05 were considered significant. Analysis was performed with the IBM SPSS program, version 20.0.

Results {#Sec7}
=======

Patient characteristics {#Sec8}
-----------------------

The clinical features of the resected rectal-cancer patients are summarized in Table [1](#Tab1){ref-type="table"}. The median age of the patients was 72 years (range 46--89 years), and male population has higher incidence (*n* = 45; 61%) with good performance status (ECOG 0) (*n* = 41; 55%).Table 1Clinico-pathologic characteristics of rectal cancer patientsCharacteristicsPatients (*N* = 74)Median age-years (range)72 (46--89)  \> 60 years60 (81%)  \< 60 years14 (19%)Sex Male45 (61%) Female29 (39%)ECOG 041 (55%) 131 (42%) 22 (3%)Status Death7 (10%) Alive without disease59 (78%) Alive with disease7 (10%) N/A1 (1%)T Downstaging 028 (38%) 139 (53%) N/A7 (9%)N Downstaging 020 (27%) 147 (64%) N/A7 (9%)Grade Low19 (26%) High47 (63%) N/A8 (11%)Stage II4 (6%) III69 (93%) N/A1 (1%)Neoadjuvant Treatment RT + Fluoropyrimidines based73 (99%) Other1 (1%)Treatment toxicity Yes30 (41%) No44 (59%)Pathological Response Complete9 (12%) Partial27 (37%) Minimun38 (51%)DEK Low26 (35%) High48 (65%)*N/A* not available, *RT* Radiotherapy

Neoadjuvant treatment was based on fluoropyrimidines (5FU or FOLFOX) and combined with radiotherapy was administered in 73 patients (99%). The majority of patients did not present treatment toxicity (*n* = 44; 59%). Concerning pathological response, complete response was achieved in 9 patients (12%) and partial and minimum response in 27 patients (37%), and 38 patients (51%) respectively.

High DEK expression associated with complete response to neoadjuvant chemoradiotherapy {#Sec9}
--------------------------------------------------------------------------------------

Based on our previous reports \[[@CR36]\], we hypothesized that DEK could be related to neoadjuvant response and serve as a predictive biomarker in patients with rectal adenocarcinoma prior to surgery. For this purpose, a tissue microarray was constructed and stained to quantify the percentage of DEK positive cells over the total number of tumour cells. All samples were obtained before the patients received neoadjuvant treatment. After immunohistochemical staining, the biopsies were observed to have nuclear localization and DEK stained only tumour cells (Fig. [1a to d](#Fig1){ref-type="fig"}). Distribution of samples according to the percentage of positive tumour cells staining showed a uniform cumulative distribution (Fig. [1e](#Fig1){ref-type="fig"}). The biopsies were then stratified into low or high DEK expression using the mean percentage of positive stained tumor cells as a cut-off point. The results showed that 9 (19%) patients out of the 45 patients with high DEK expression achieved a complete response to neoadjuvant treatment; while none of those with low DEK expression obtained a complete response. In fact, all patients who showed complete response (*n* = 9) had high DEK expression. Moreover, 82% of patients (*n* = 39) with high expression achieved partial or minimal response, while all patients (*n* = 26; 100%) with low DEK expression achieved partial or none response (Table [2](#Tab2){ref-type="table"}). Statistical analysis showed significant differences between both groups of response to neoadjuvant chemoradiotherapy (complete vs. partial or minimal) and the low or high DEK expression (*Chi-squared: P =* 0,018*; Fisher's exact: P =* 0,023) (Table [2](#Tab2){ref-type="table"}).Fig. 1Differential pattern of DEK positive stained cells of locally advanced rectal tumours. **a** and **b** representative images of tumour samples with high percentage of DEK positive stained cells. **c** and **d** representative images of tumour samples with low percentage of DEK positive stained cells. Scale bar is 50 μm. **e** Histogram of patient samples according to percentage of DEK positive tumour cellsTable 2Statistical association between neoadjuvant treatment response and low- or high-percentage of DEK positive tumor cellsTreatment ResponseDEKNo. Complete (% of DEK subpopulation)No. Partial or minimum (% of DEK subpopulation)*P* (chi-square)*P* (Fisher)High939* n* = 48(19%)(82%)0,0180,023Low026* n* = 26(0%)(100%)*No* Number of patients

Further analysis revealed no statistical association between DEK expression and the rest of the clinicopathologic variables studied, including gender (*P* = 0.553), age (*P* = 0.758), T-downstaging (*P* = 0.840), N-downstaging (*P* = 0.626), grade (*P* = 0.312), ECOG (*P* = 0.843), status (*P* = 0.544), tumour size (*P* = 0.703), and stage (*P* = 0.613). Concerning treatment toxicity, a considerable trend was observed between high DEK expression and the absence of treatment toxicity (*P =* 0.086*)* (Table [3](#Tab3){ref-type="table"}).Table 3Statistical association between low- or high-percentage of DEK positive stained tumor cells and clinico-pathological parametersDEKParameterLowHigh*P*Gender0.553 Male1728 Female920Age0.758  \< 60 years410  \> 60 years2238T_Downstaging0.840 No1018 Yes1326N_Downstaging0.626 No614 Yes1730Grade0.312 Low910 High1631Treatment toxicity0.086 Yes1416 No1232ECOG0.843 01427 1--21221Status0.544 Alive with disease or death68 Alive without disease2040Tumor size0.703  \<  3 cm26  \>  3 cm2441Stage0.613 II22 III2445

DEK expression associated with phospho-P38 expression in pre-treated rectal cancer biopsies {#Sec10}
-------------------------------------------------------------------------------------------

P38 is an important component of the mitogen-activated protein kinases (MAPK) \[[@CR40]\] and plays a central role in cell proliferation and apoptosis in multiple neoplasias \[[@CR41]\]. Furthermore, P38 has been recently associated to chemotherapy response in colorectal cancer \[[@CR42]\]. Therefore, we quantified the immunoreactivity of the active form of P38 (phospho-P38) in all rectal cancers biopsies by immunohistochemistry. Phospho-P38 expression was then categorized as low or high according to median percentage of positive stained tumor cells as cut-off point. Although we did not find statistically significant association between phospho-P38 expression and pathological response to neoadjuvant treatment (*P* = 0.296; data not shown), a direct association was found between phospho-P38 and DEK expression (*P* = 0.027; Table [4](#Tab4){ref-type="table"}). In fact, seven patients of whom showed not only complete response but also high DEK expression (*n* = 9) revealed high expression of phospho-P38, while two patients presented low phospho-P38 expression.Table 4Statistical association between phospho-P38 and DEK positiveness in rectal cancer patients treated with neoadjuvant chemoradiotherapyDEK \\ phospho-P38LowHighTotal*P* (chi-square)Low151530(%)(20%)(20%)(40%)High113344(%)(15%)(45%)(60%)Total2648740,027(%)(35%)(65%)(100%)Table 5Dataset of patient biopsies recruited in the studyBiopsyAgeECOG_PSStatusT-DownstagingN-DownstagingGradeStageNeoadjuvant treatmentTreatment toxicityPathological ResponseTumor sizeDEK (% positive tumor cells)Phospho-P38 (% positive tumor cells)1\> 701alive without disease01HighIIIRDT + FOLFOXNoPartial\>  3 cm3352\> 601alive without disease01HighIIIRDT + 5FUNoMinimum\>  3 cm3353\> 700Death10HighIIIRDT + FOLFOXYesMinimum\<  3 cm7654\> 700alive without disease01LowIIIRDT + 5FUNoMinimum\>  3 cm10805\> 600alive with desease01LowIIIRDT + FOLFOXYesMinimum\>  3 cm15456\> 700alive without disease11HighIIIRDT + FOLFOXYesPartial\>  3 cm15807\> 400alive with desease00HighIIIRDT + 5FUYesPartial\>  3 cm20258\> 401alive with desease10HighIIRDT + 5FUYesMinimum\>  3 cm20259\> 700alive without disease11LowIIIRDT + 5FUNoPartial\>  3 cm304510\> 700alive without disease11HighIIIRDT + FOLFOXYesMinimum\>  3 cm355511\> 700alive without diseaseN/AN/AHighIIIRDT + FOLFOXNoMinimum\>  3 cm351012\> 500alive without disease01HighIIIRDT + 5FUYesMinimum\>  3 cm357013\> 700alive without disease11HighIIIRDT + 5FUNoPartial\>  3 cm352514\> 500alive without disease11LowIIIRDT + 5FUNoMinimum\>  3 cm352515\> 701alive without disease11HighIIIRDT + 5FUYesMinimum\<  3 cm359016\> 601alive without disease11LowIIIRDT + 5FUNoPartial\>  3 cm359017\> 600N/A00HighIIIRDT + FOLFOXYesMinimum\>  3 cm40518\> 800Death10HighIIIRDT + 5FUYesPartial\>  3 cm409019\> 701alive without disease01LowIIIRDT + 5FUYesMinimum\>  3 cm408520\> 600alive without disease01HighIIIRDT + 5FUNoMinimum\>  3 cm406521\> 702alive without disease10N/AIIRDT + 5FUYesMinimum\>  3 cm4010022\> 701Death01HighIIIRDT + 5FUYesPartial\>  3 cm456523\> 801alive without diseaseN/AN/AHighIIIRDT + 5FUNoPartial\>  3 cm454024\> 701alive without diseaseN/AN/ALowIIIRDT + 5FUYesPartial\>  3 cm458025\> 801alive without disease11LowIIIRDT + 5FUNoPartial\>  3 cm508026\> 701alive without disease11LowIIIRDT + 5FUNoPartial\>  3 cm558027\> 500alive without disease11HighIIIRDT + FOLFOXYesMinimum\>  3 cm608028\> 801alive without diseaseN/AN/AHighN/ARDT + 5FUNoComplete\>  3 cm606029\> 801alive without disease11HighIIIRDT + FOLFOXYesMinimum\>  3 cm607530\> 600alive without disease00HighIIIRDT + 5FUNoMinimum\>  3 cm604031\> 501alive with desease11HighIIIRDT + 5FUNoComplete\<  3 cm6010032\> 600alive without diseaseN/AN/AHighIIIRDT + 5FUNoComplete\>  3 cm604533\> 400alive without disease00HighIIIRDT + FOLFOXYesMinimum\>  3 cm6510034\> 800alive without disease11HighIIIRDT + 5FUYesPartial\>  3 cm657535\> 800alive without disease10HighIIIRDT + 5FUNoPartial\>  3 cm657536\> 801alive without disease11N/AIIIRDT + 5FUYesPartial\<  3 cm659037\> 700alive without disease11N/AIIIRDT + 5FUNoComplete\>  3 cm659038\> 701alive without disease11LowIIIRDT + 5FUNoMinimum\>  3 cm651539\> 600alive without disease11HighIIIRDT + 5FUNoPartial\>  3 cm658040\> 601alive without disease10HighIIIRDT + 5FUNoPartial\>  3 cm655041\> 400alive without disease11LowIIIRDT + 5FUYesPartial\>  3 cm706042\> 801alive without disease11HighIIIRDT + 5FUNoComplete\>  3 cm758043\> 700alive with desease10LowIIIRDT + FOLFOXNoMinimum\<  3 cm759044\> 701alive without diseaseN/AN/AHighIIIRDT + 5FUNoMinimum\>  3 cm757545\> 400alive without disease11N/AIIIRDT + 5FUNoComplete\>  3 cm759546\> 600alive without disease11LowIIIRDT + 5FUYesComplete\<  3 cm759047\> 801alive without disease01HighIIIRDT + 5FUYesMinimum\>  3 cm759548\> 601alive with desease01HighIIIRDT + 5FUYesComplete\>  3 cm757049\> 700Death11LowIIIothersYesMinimum\<  3 cm80350\> 801Death00HighIIIRDT + FOLFOXYesMinimum\>  3 cm803551\> 700alive without disease00HighIIIRDT + 5FUNoPartial\>  3 cm8010052\> 600alive without disease01HighIIIRDT + 5FUYesPartial\<  3 cm809553\> 701alive without disease10N/AIIIRDT + 5FUNoPartial\>  3 cm803054\> 600alive without disease00N/AIIRDT + 5FUNoPartial\>  3 cm801055\> 701alive without disease11N/AIIIRDT + FOLFOXNoPartial\>  3 cm859056\> 801alive without disease01HighIIIRDT + 5FUYesMinimum\>  3 cm854557\> 500alive without disease11LowIIIRDT + 5FUNoPartial\>  3 cm857558\> 501alive without disease00HighIIIRDT + 5FUNoMinimum\>  3 cm858559\> 600alive without disease11LowIIIRDT + 5FUNoPartial\>  3 cm853060\> 801alive without disease11HighIIIRDT + 5FUNoMinimum\>  3 cm858061\> 600alive without disease11LowIIIRDT + 5FUNoPartial\>  3 cm85062\> 500alive without diseaseN/AN/ALowIIIRDT + FOLFOXNoMinimum\>  3 cm8510063\> 701alive without disease11HighIIIRDT + 5FUNoMinimumN/A909564\> 700alive without disease01HighIIIRDT + 5FUNoMinimum\>  3 cm908565\> 701Death00HighIIIRDT + 5FUYesMinimum\>  3 cm904566\> 500alive without disease11LowIIIRDT + 5FUNoMinimum\>  3 cm905567\> 602Death00HighIIIRDT + 5FUYesMinimum\>  3 cm9510068\> 700alive without disease10N/AIIRDT + 5FUNoMinimum\>  3 cm958569\> 600alive without disease01HighIIIRDT + 5FUNoPartial\>  3 cm958070\> 600alive without disease01HighIIIRDT + 5FUYesMinimum\>  3 cm959071\> 700alive with desease01HighIIIRDT + 5FUNoMinimum\>  3 cm957572\> 700alive without disease10HighIIIRDT + 5FUNoComplete\>  3 cm957573\> 801alive without disease01HighIIIRDT + 5FUNoMinimum\>  3 cm1007574\> 501alive without disease01HighIIIRDT + 5FUNoMinimum\>  3 cm10080*N/A* Not available, *RDT* radiotherapy

These results suggest that high DEK expression in tumour biopsies could be used as a potential biomarker of pathological response that follows neoadjuvant therapy in rectal cancer. Moreover, the association between DEK and phospho-P38 expression supports and provides a highly robust predictive model of cell-death revealed by the complete response to neoadjuvant treatment.

Discussion {#Sec11}
==========

Neoadjuvant chemoradiotherapy is the standard care approach for stage II and III rectal-cancer patients. The aim of this treatment is to achieve pathologic downstaging and complete response. Therefore, extensive investigation is currently being devoted to biomarkers that predict response to neoadjuvant treatment. Genetic profiling platforms have become a useful tool for analyzing DNA, RNA, and other factors that may or may not be translated into protein, such as miRNA. In the era of genomics, transcriptomics, and proteomics, these methodologies have helped elucidate potential biomarkers of treatment response in rectal cancer \[[@CR17], [@CR43]--[@CR47]\]. DNA microarrays have been used to differentiate rectal-cancer patients into responders and non-responders. A study using DNA microarrays to assess 17 rectal-cancer samples discovered 17 genes differentially expressed between responders and non-responders \[[@CR44]\]. Some of these genes included *MMP*, *NFKB2*, *TGFB1*, *TOP1*, and *ITGB1* \[[@CR44]\]. The most highly overexpressed gene, *MMP7*, was validated by immunohistochemistry, and it was found that none of the non-responders (*n* = 7) overexpressed the gene. However, only four of the responders (*n* = 10) overexpressed MMP7 \[[@CR44]\]. Palma et al. analyzed the gene-expression profiles of 26 pre-treatment biopsies by expression microarray and demonstrated that high levels of Gng4, c-Myc, Pola1, and Rrm1 expression were significant factors when predicting neoadjuvant response in rectal cancer \[[@CR45]\]. Others studies with 23 patient samples \[[@CR17]\] and with 43 patient samples \[[@CR43]\] revealed 54 and 43 differentially expressed genes, respectively, though no concordance was found between both studies. Some studies based on miRNA microarrays revealed higher miR-223 levels in responders compared to non-responders, one in a cohort of 43 rectal-cancer patients \[[@CR46]\], and a more recent in a cohort of 59 patients \[[@CR47]\].

Post-translational modifications may affect the concordance between gene-expression profile and protein-expression pattern, which could lead to controversial results. Proteins are the main agents in biologic pathways, and thus the results of protein-expression analysis may be the key to treatment decision-making. Regarding the prediction of response to chemoradiotherapy in rectal cancer by immunohistochemistry, Kuremsky et al. reported that the most commonly biomarkers evaluated were p53, EGFR, TYMS, Ki-67, p21, BCL-2, and BAX \[[@CR48]\].

High DEK expression has been described previously by our group as a crucial event for aggressive tumour phenotype and as a biomarker for poor response to irinotecan in metastatic colorectal cancer \[[@CR36]\]. In the present study, high DEK expression was related to pathological response in 74 locally advanced rectal adenocarcinomas. This enabled us to establish a new model based on DEK expression that was statistically associated with complete pathological response. Here, it is supported that rectal cancer patients with high DEK expression have a 19% probability to achieve complete response. Otherwise, low DEK expression predicts lack of complete response to neoadjuvant treatment. Moreover, the fact that DEK expression associated with the pro-apoptotic factor P38 supports the role of DEK as a predictive biomarker for pathological complete response to chemoradiotherapy prior to surgery in rectal cancer patients.

The findings showed in the present study seem to disagree with those obtained in our previous work with colorectal cancer \[[@CR36]\]. However, our previous research was performed with stage IV colorectal cancer samples, while the present work only focused on stage II--III rectal tumours that only represent a part of colorectal tumors. Moreover, the potential effect of DEK in our previous study to predict irinotecan response was not observed with 5FU or oxaliplatin, drugs used in the present study to evaluate pathological response. Indeed, DEK has also been related to neoadjuvant treatment response in breast cancer, independently of estrogen-receptor status \[[@CR49]\]. Consequently, our study agree with Witkiewicz et al., who reported a strong association between high DEK expression and a low residual cancer burden, indicative of preferred response to neoadjuvant chemotherapy \[[@CR49]\].

Conclusions {#Sec12}
===========

This retrospective study supports DEK as a potential predictive biomarker for neoadjuvant treatment response in rectal cancer. Moreover, the methodology performed here is easy and reproducible enough to be implemented in the routine clinical practise.

Although further research is needed, this preliminary study could be used to prospectively validate the predictive value of DEK expression in rectal and other types of tumours prior neoadjuvant treatment.
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